Revenio Group (REG1V) CMD 2026 summary
Event summary combining transcript, slides, and related documents.
CMD 2026 summary
18 Sep, 2026Strategic direction and market positioning
Transitioning from traditional vision care to connected eye health, leveraging device and software innovations and the expanded portfolio from the Visionix acquisition.
Addressable market expanded from €1.1bn/$1.1bn to €2.7bn/$2.7bn, with a strengthened global presence and broader product portfolio, especially in OCT and multimodal diagnostics.
Four strategic cornerstones: advancing clinical confidence and workflow excellence, commercial excellence, operational excellence, and people/culture development.
Strategy builds on previous goals of connected and predictive eye care, now emphasizing sustainable, profitable growth and global reach.
Differentiators include efficiency, clinical confidence, ease of use, and innovation across the portfolio.
Product and solution portfolio
Comprehensive offering spans essential to advanced diagnostics, including tonometry, fundus imaging, OCT, perimetry, and cloud-based solutions.
Cloud platform enables data capture, transfer, analysis, and AI-supported decision-making across clinical settings.
Portfolio enables clinical role expansion for optical retail and optometry, supporting broader access and workflow excellence.
Continuous innovation and integration of Visionix products enhance the value proposition.
Focus on enabling optical retail and optometry to take on more clinical roles, supported by technology and education.
Commercial and operational integration
Combined commercial footprint covers over 400 distributors in 130+ markets, with expanded direct sales in major global markets.
Integration has achieved 25% of the planned €20m EBITDA uplift within the first 100 days, targeting full realization by 2029.
Operational model balances in-house and outsourced manufacturing, simplifies supply chains, and harmonizes customer care.
Unified culture and high-performing organization are critical enablers for future success.
Recurring revenue now represents 20% of sales, with ambitions to grow through bundled software and service offerings.
Latest events from Revenio Group
- Q2 net sales up 48.1% as Visionix boosted growth but pressured margins and leverage.REG1V
Q2 2026 - Net sales rose 4.8% but profit dropped on Visionix costs; acquisition expands market reach.REG1V
Q1 2026 - Merger forms a top global eye care leader, targeting EUR 20m+ synergies and rapid growth.REG1V
M&A announcement - 2025 net sales up 6% to EUR 109.7M, record cash flow, and 2026 sales growth expected at 8–15%.REG1V
Q4 2025 - Q3 2025 saw strong sales and profitability, with 6–15% sales growth forecast for 2025.REG1V
Q3 2025 - Q3 net sales up 8.9%, operating profit down, AI diagnostics strengthened by Thirona Retina.REG1V
Q3 2024 - Q2 net sales up 14.2%, strong cash flow, and 2024 sales growth guidance of 5–10%.REG1V
Q2 2024 - Record Q1 sales and profit, driven by global growth and strong financials.REG1V
Q1 2025 - Record sales, robust cash flow, and 2025 guidance for up to 15% growth amid global risks.REG1V
Q4 2024